GlassScriptPhysician profile
Karen Evans
NPI 1992758957
$2,490.21
in general payments reported to CMS, 2019-2025
26 companies · $979 in 2025
The $979 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2020: $39.50 · 2022: $103 · 2023: $332 · 2024: $921 · 2025: $979.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,232.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $316.75 | 2022-2025 | |
| Lilly USA, LLC | $267.74 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $235.25 | 2019-2025 | Rybelsus, Wegovy, Ozempic |
| Pfizer INC. | $220.70 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $196.03 | 2023-2025 | Dupixent |
| Abbott Laboratories | $185.22 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astellas Pharma US INC | $144.93 | 2023-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $130.27 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Dexcom, INC. | $115.92 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $111.26 | 2023-2024 | Xifaxan |
| Amgen INC. | $109.75 | 2019-2025 | Repatha, Otezla, Evenity |
| Noven Therapeutics, LLC | $94.68 | 2024 | Xelstrym |
| Axsome Therapeutics, INC. | $77.07 | 2024 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $39.83 | 2023-2025 | Rexulti |
| Medtronic, INC. | $35.42 | 2023 | Intellis Adaptivestim |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $30.87 | 2025 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.10 | 2019-2025 | Jardiance |
| Nalu Medical, INC. | $24.74 | 2025 | Nalu Neurostimulation System |
| Agile Therapeutics, INC. | $18.08 | 2024 | Twirla |
| E.R. Squibb & Sons, L.L.C. | $17.86 | 2019 | |
| Glaxosmithkline, LLC. | $16.00 | 2025 | Shingrix, Bexsero, Arexvy |
| Philips North America LLC | $15.68 | 2024 | (Ak6) Vest Therapy |
| Phathom Pharmaceuticals, INC. | $15.55 | 2024 | Voquezna |
| Exact Sciences Corporation | $15.43 | 2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $13.78 | 2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $11.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.